GlassScriptPhysician profile
Shilpa Gupta
NPI 1659588754
$3,601.72
in general payments reported to CMS, 2019-2025
23 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.78 · 2020: $13.54 · 2021: $59.95 · 2022: $269 · 2023: $2,505 · 2024: $361 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,070 · Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,070.00 |
| Food and Beverage | $1,165.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,070.00 | 2023 | |
| Ascendis Pharma Endocrinology INC | $288.05 | 2022-2024 | |
| Tolmar, INC. | $240.44 | 2023-2024 | |
| Tolmar Pharmaceuticals, INC. | $196.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $134.98 | 2025 | |
| Abbvie INC. | $91.44 | 2023-2025 | |
| Glaxosmithkline, LLC. | $86.43 | 2022-2025 | Nucala, Bexsero, Pediarix |
| Dexcom, INC. | $81.29 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $79.32 | 2024-2025 | Sogroya, Wegovy |
| Abbott Laboratories | $58.26 | 2023-2025 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $31.25 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.00 | 2025 | |
| Medtronic, INC. | $27.55 | 2023 | Inpen Smart Insulin Delivery System |
| Sanofi Pasteur INC. | $24.80 | 2024 | |
| Ironshore Pharmaceuticals INC. | $22.78 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.22 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $20.52 | 2025 | |
| Nestle Healthcare Nutrition INC. | $20.38 | 2023 | |
| Kyowa Kirin, INC. | $16.83 | 2025 | |
| Insulet Corporation | $16.71 | 2024 | Omnipod |
| Tandem Diabetes Care, INC. | $15.08 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Puma Biotechnology, INC. | $13.54 | 2020 | |
| Embecta Corp. | $13.37 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.